Eli Lilly acquires Merida Biosciences for up to $2.875B, gaining MER511 for thyroid eye disease/Graves' disease and MER769 ...
Sanofi-backed Electra files for a Nasdaq IPO to fund Phase 2/3 trials of ipsoprubart, its lead antibody for the rare disease ...
Nine more drugmakers strike voluntary drug-pricing deals with the White House, pledging nearly $20B in US investments to avoid tariffs and CMS pricing pilots.
AstraZeneca's oral relaxin drug AZD5462 hits its HFpEF endpoint but narrowly misses in HFrEF in the Phase 2b LUMINARA heart ...
CRISPR Therapeutics’ gene editing candidate showed mixed durability results a year after patients were dosed, according to ...
BioNTech said Friday that it ended a mid-stage trial that was testing autogene cevumeran as an adjuvant monotherapy in ...
FDA approves Roivant's Lisraya (brepocitinib), first oral drug for dermatomyositis; TD Cowen sees $5B–$10B potential across ...
Lilly's Mounjaro wins a CV nod, Teva buys BioXcel's assets, AusperBio raises $120M and Samsung Biologics preps a $2.2B raise.
Haisco Pharma partners with ARCH Venture's Bob Nelsen & Population Health Partners' Clive Meanwell to launch Sentivera in a ...
Gilead's FDA-approved Bixlenvo (BIC/LEN), a grain-of-rice-sized once-daily HIV pill, targets virologically suppressed ...
MassBio report shows MA biopharma jobs fell 3.1%, NIH awards dropped 6%, while China's drug pipeline grew 36% in 2025, ...
Fifth Circuit rejects PhRMA's challenge to Medicare drug-price negotiation, ending pharma's first wave of IRA litigation.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results